Zentek Ltd Dossier
|
SectorHealth Care IndustryHealth Care Equipment Beta (adjusted)0.62 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $0.49Price as of 1 Sep 2026 Data confidenceNot applicable Market Cap $62.3M Enterprise Value $62.9M Shares Outstanding 126.6M diluted Next Earnings Date12 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Zentek Ltd. is undergoing a critical strategic reset under its new CEO, Moe Jiwan, who took office in December 2025. The company has narrowed its focus to three core platforms: Albany Graphite, ZenGUARD, and Triera Biosciences, while pausing non-core initiatives to preserve capital. Although Zentek has achieved significant technical milestones—such as demonstrating nuclear-grade purity (99.9992%) for its Albany graphite and securing Health Canada commercial classification and direct federal procurement pathways for its ZenGUARD air filters—the company remains in a pre-revenue, highly speculative phase. With trailing twelve-month revenues under $1M CAD and persistent net losses, the investment case hinges on successful commercial execution and the upcoming Summer 2026 Preliminary Economic Assessment (PEA) for Albany Graphite. A 'Hold' rating is recommended until clear commercial traction and capital discipline are demonstrated. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario The bear case involves commercialization delays for ZenGUARD, disappointing economics in the Albany PEA, and failure to regain compliance with Nasdaq's minimum bid price, leading to delisting. Continued high cash burn would force highly dilutive equity raises at depressed valuations. Base CaseCentral scenario The base case assumes Zentek successfully delivers its updated Albany Graphite PEA in Summer 2026, confirming robust economics for nuclear and defense applications. ZenGUARD air filters begin generating steady commercial revenue from Canadian federal departments and commercial HVAC partners. Triera Biosciences establishes its first contract research organization (CRO) custom aptamer discovery contracts, gradually reducing the company's cash burn rate. Bull CaseUpside scenario Successful commercialization of ZenGUARD in the US HVAC market and a highly favorable Preliminary Economic Assessment (PEA) for the Albany Graphite Project rerate the stock as a critical national security asset. Scenarios reflect our research view at the research date. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |